The Vitiligo market growth is driven by factors like increase in the prevalence of Vitiligo, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Vitiligo market report also offers comprehensive insights into the Vitiligo market size, share, Vitiligo epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Vitiligo market size growth forward.
Some of the key highlights from the Vitiligo Market Insights Report:
Several key pharmaceutical companies, including Incyte Corporation, Amgen, Boston Pharmaceuticals, Arcutis Biotherapeutics, Pfizer, Dermavant Sciences, Clinuvel Pharmaceuticals, Celgene, TWi Biotechnology, AXIM Biotechnologies, Arrien Pharmaceuticals, and others, are developing novel products to improve the Vitiligo treatment outlook.
The total Vitiligo market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Vitiligo market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Vitiligo Market Landscape
Vitiligo is a complex pigment disorder that involves the skin, the hair, and occasionally the mucous membranes. It is a long-term condition where pale white patches develop on the skin. Vitiligo can affect any area of skin, but it commonly happens on the face, neck and hands. Vitiligo appears clinically as milk-white irregularly oval patches of skin, which are small at the beginning but enlarge gradually. The hair growing in the depigmented area is also white. Vitiligo can be triggered by stress to the melanin pigment-producing cells of the skin, the melanocytes. The triggers, which range from sunburn to mechanical trauma and chemical exposures, ultimately cause an autoimmune response that targets melanocytes, driving progressive skin depigmentation.
Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. Multiple mechanisms have been proposed for melanocyte destruction in vitiligo. These include genetic, autoimmune responses, oxidative stress, generation of inflammatory mediators and melanocyte detachment mechanisms. Both innate and adaptive immunity of the immune system appear to play a role.
The diagnosis of vitiligo is primarily made on clinical grounds and is based on history, clinical presentation, and family history (vitiligo, autoimmune disorders). The most extensively characterized clinical markers of active, progressive disease include: Koebner’s phenomenon, trichrome lesions, inflammatory lesions and confetti-like depigmentation.
The optimal treatment of vitiligo will first depend on the subtype of the disease, percent of body surface area (BSA) involved, effect on quality of life, and the perception of the patient concerning the risk to benefit ratio. These treatments include phototherapy, topical and systemic immunosuppressants, and surgical techniques, stabilizing depigmented lesions and stimulating repigmentation. A successful treatment regimen to treat vitiligo incorporates three distinct approaches: reducing melanocytes stress, regulating the autoimmune response, and stimulating melanocyte regeneration.
Do you know the treatment paradigms for different countries? Download our Vitiligo Market Sample Report
Recent Breakthroughs in the Vitiligo Market
AVITA scores US FDA approval for vitiligo treatment: AVITA Medical (ASX: AVH) has achieved a ‘breakthrough approval’ with the US Food and Drug Administration (FDA) by gaining pre-market approval for its RECELL system to treat vitiligo, an autoimmune disease that causes discoloration of the skin and affects around 2 per cent of the global population.
In September 2020, TAGCyx biotechnologies entered into a research collaboration with CAGE Bio for development of TAGX-0003 for treatment of dermatological autoimmune skin diseases. TAGX-0003 is a DNA aptamer possessing potent IFN-γantagonistic activity developed by TAGCyx and has already shown effective data in humanized autoimmune skin disease animal model such as alopecia areata when intra-dermally injected.
Vitiligo Epidemiology Segmentation
DelveInsight’s Vitiligo market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Vitiligo historical patient pools and forecasted Vitiligo patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Vitiligo Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Age-Specific Vitiligo Prevalence
Gender-Specific Vitiligo Prevalence
Diagnosed and Treatable Cases of Vitiligo
Visit for more @ Vitiligo Epidemiological Insights
Vitiligo Treatment Market
The Vitiligo market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Vitiligo market trends by analyzing the impact of current Vitiligo therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Vitiligo market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Vitiligo market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Vitiligo market in 7MM is expected to witness a major change in the study period 2019-2032.
Vitiligo Emerging Drugs
Ruxolitinib: Incyte Corporation
Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The therapy is currently under Phase III clinical development for the treatment of vitiligo.
AMG-714, a fully human immunoglobulin monoclonal antibody (IgG1κ), binds to and inhibits the function of IL-15 in all of its forms (Cis, Trans, and soluble IL-15 bound to IL-15RA), and blocks IL-15-induced T cell proliferation. The molecule is currently in Phase II clinical evaluation for the treatment of vitiligo.
Vitiligo Key Companies
For more information, visit Vitiligo Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Vitiligo Market Report:
11 Years Forecast
Descriptive overview of Vitiligo, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Vitiligo epidemiology in the 7MM
Vitiligo marketed and emerging therapies
Vitiligo market drivers and barriers
Key Questions Answered in the Vitiligo Market Report 2032:
What was the Vitiligo market share distribution in 2019, and how would it appear in 2032?
What is the total Vitiligo market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Vitiligo market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Vitiligo market projected to expand at 7MM?
Table of Contents:
1 Vitiligo Market Key Comprehensive Insights
2 Vitiligo Market Report Introduction
3 Competitive Intelligence Analysis for Vitiligo
4 Vitiligo Market Analysis Overview at a Glance
5 Executive Summary of Vitiligo
6 Vitiligo Epidemiology and Market Methodology
7 Vitiligo Epidemiology and Patient Population
8 Vitiligo Patient Journey
9 Vitiligo Treatment Algorithm, Vitiligo Current Treatment, and Medical Practices
10 Key Endpoints in Vitiligo Clinical Trials
11 Vitiligo Marketed Therapies
12 Vitiligo Emerging Therapies
13 Vitiligo: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Vitiligo
16 Vitiligo Market Key Opinion Leaders Reviews
18 Vitiligo Market Drivers
19 Vitiligo Market Barriers
20 SWOT Analysis
22 DelveInsight Capabilities
23 About DelveInsight
Vitiligo Epidemiology 2032
DelveInsight’s “Vitiligo – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Vitiligo epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Vitiligo Pipeline 2023
“Vitiligo Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Vitiligo market. A detailed picture of the Vitiligo pipeline landscape is provided, which includes the disease overview and Vitiligo treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States